JOP20250007A1 - دواء لخفض كوليسترول ldl بالدم - Google Patents

دواء لخفض كوليسترول ldl بالدم

Info

Publication number
JOP20250007A1
JOP20250007A1 JOJO/P/2025/0007A JOP20250007A JOP20250007A1 JO P20250007 A1 JOP20250007 A1 JO P20250007A1 JO P20250007 A JOP20250007 A JO P20250007A JO P20250007 A1 JOP20250007 A1 JO P20250007A1
Authority
JO
Jordan
Prior art keywords
blood
medication
ldl cholesterol
lower ldl
ldl
Prior art date
Application number
JOJO/P/2025/0007A
Other languages
Arabic (ar)
English (en)
Inventor
Ryohei TANIGAWA
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of JOP20250007A1 publication Critical patent/JOP20250007A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2025/0007A 2022-07-15 2025-01-13 دواء لخفض كوليسترول ldl بالدم JOP20250007A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022113930 2022-07-15
PCT/JP2023/025980 WO2024014524A1 (ja) 2022-07-15 2023-07-14 血中ｌｄｌコレステロール低下剤

Publications (1)

Publication Number Publication Date
JOP20250007A1 true JOP20250007A1 (ar) 2025-01-13

Family

ID=89536850

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0007A JOP20250007A1 (ar) 2022-07-15 2025-01-13 دواء لخفض كوليسترول ldl بالدم

Country Status (8)

Country Link
US (1) US20260014122A1 (https=)
EP (1) EP4556006A4 (https=)
JP (1) JPWO2024014524A1 (https=)
KR (1) KR20250034041A (https=)
CN (1) CN119546300A (https=)
JO (1) JOP20250007A1 (https=)
TW (1) TW202408500A (https=)
WO (1) WO2024014524A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) * 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20240277745A1 (en) * 2021-05-27 2024-08-22 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease

Also Published As

Publication number Publication date
WO2024014524A1 (ja) 2024-01-18
KR20250034041A (ko) 2025-03-10
EP4556006A4 (en) 2026-01-07
CN119546300A (zh) 2025-02-28
TW202408500A (zh) 2024-03-01
EP4556006A1 (en) 2025-05-21
US20260014122A1 (en) 2026-01-15
JPWO2024014524A1 (https=) 2024-01-18

Similar Documents

Publication Publication Date Title
GB0410266D0 (en) Treatment of apoptosis
JP2017075183A5 (https=)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
MX2010004508A (es) Suministro de agentes activos.
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
US20190216886A1 (en) Topical Compositions And Methods For Treating Wounds
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2021502392A5 (https=)
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2021022058A3 (en) Antiarrhythmic formulation
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
Kumar et al. A review on pharmaceutical, pharmacological and chemical aspects of serratiopeptidase as anti-inflammatory agent
JOP20250007A1 (ar) دواء لخفض كوليسترول ldl بالدم
ATE481094T1 (de) Behandlung von diabetischer nephropathie
PH12023552967A1 (en) Blood carnitine-increasing agent
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
MA58327B2 (fr) Nouveau composé de [2-(diméthylamino)-2-phénylbutyl]-3,4,5-triméthoxybenzoate 4-méthyl-2н-chromen-2-one-7-ylsulfate et son utilisation
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
IL320111A (en) Cnp compounds
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
PH12023553231A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
BR112022025900A2 (pt) Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
RU2609017C1 (ru) Способ лечения грибковых заболеваний ногтей
RU2066186C1 (ru) Средство для купирования приступов удушья при бронхиальной астме
Chandawat et al. Role of tamsulosin in the management of lower ureteric stone at tertiary care hospital in Western Rajasthan, India